What is the 13F Pro Quality Score for ZNTL?

13F Pro ranks Zentalis Pharmaceuticals, Inc. (ZNTL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ZNTL's current score at https://13fpro.ai/company/ZNTL (free sign-up required for the full ranking).

Which hedge funds own the most ZNTL stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ZNTL include 5AM Venture Management,, BlackRock,, Squadron Capital Management. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/ZNTL as soon as new 13F filings post.

Where does 13F Pro source ZNTL data?

All Zentalis Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Zentalis Pharmaceuticals, Inc. files with the SEC under CIK 1725160. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ZNTL in?

Zentalis Pharmaceuticals, Inc. (ZNTL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ZNTL research updated on 13F Pro?

ZNTL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Zentalis Pharmaceuticals, Inc.(ZNTL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1725160 ZNTL stock profile & AI dashboard →

13F Pro Quality Score

11.6/100

Rank #2,719 of 2,777 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

30.0/100

Profitability

2.8/100

Balance Sheet

5.9/100

Earnings Quality

16.0/100

Free Cash Flow

2.8/100

Institutional Flow

1.8/100

Revenue Scale

5.6/100

Dilution Risk

2.7/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ZNTL Scores 12/100

exact factor attribution · 2026-03-20

ZNTL's composite is held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings growth

-1.0 pts

30th pct

Shareholder dilution

-2.4 pts

3th pct

Institutional flow

-2.4 pts

2th pct

Earnings quality

-3.4 pts

16th pct

Revenue growth

-4.0 pts

30th pct

Capital efficiency

-4.4 pts

6th pct

Scale

-6.7 pts

6th pct

Profitability

-7.1 pts

3th pct

Free cash flow

-7.1 pts

3th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

ZNTL Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for Zentalis Pharmaceuticals, Inc. (ZNTL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ZNTL at 11.6/100 on a 32-signal composite quality model, placing it at rank #2,719 of 2,777 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (1.8) and profitability (2.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Zentalis Pharmaceuticals, Inc. reports net income of $-42.3M, free cash flow of $-37.2M. Top institutional holders of ZNTL by reported 13-F value include 5AM Venture Management, BlackRock, Squadron Capital Management, based on the most recent SEC filings. ZNTL trades on the Nasdaq exchange and files with the SEC under CIK 1725160. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ZNTL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Zentalis Pharmaceuticals, Inc. directly from SEC EDGAR. Zentalis Pharmaceuticals, Inc.'s 13F Pro composite quality score has ranged between 11 and 12 since 2026, currently 11.6 — a stable long-term trajectory across 23 quarterly and live scoring snapshots.

Net Income

Q2 2026

$-42.3M

Free Cash Flow

Q2 2026

$-37.2M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-100.0% YoY

$0.00FY 2025

FY22 $0.00FY23 $0.00FY24 $67.4MFY25 $0.00

Net Income

+17.4% YoY

$-137.1MFY 2025

FY22 $-236.8MFY23 $-292.2MFY24 $-165.8MFY25 $-137.1M

Operating Income

+20.1% YoY

$-152.8MFY 2025

FY22 $-227.3MFY23 $-299.5MFY24 $-191.2MFY25 $-152.8M

EPS (Diluted)

+18.0% YoY

$-1.91FY 2025

FY22 $-4.48FY23 $-4.47FY24 $-2.33FY25 $-1.91

Total Assets

-32.9% YoY

$289.0MFY 2025

FY22 $539.3MFY23 $551.7MFY24 $430.3MFY25 $289.0M

Op. Cash Flow

+26.7% YoY

$-125.2MFY 2025

FY22 $-163.8MFY23 $-207.8MFY24 $-170.9MFY25 $-125.2M

Free Cash Flow

+26.8% YoY

$-125.2MFY 2025

FY22 $-166.3MFY23 $-208.4MFY24 $-171.1MFY25 $-125.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$0.00 -100.0%	$67.4M	$0.00	$0.00	—	—
Net Income	$-137.1M +17.4%	$-165.8M +43.2%	$-292.2M -23.4%	$-236.8M -49.2%	$-158.7M -34.7%	$-117.8M
Operating Income	$-152.8M +20.1%	$-191.2M +36.2%	$-299.5M -31.8%	$-227.3M -5.0%	$-216.5M -82.3%	$-118.8M
EPS (Diluted)	$-1.91 +18.0%	$-2.33 +47.9%	$-4.47 +0.2%	$-4.48 -20.4%	$-3.72 +11.2%	$-4.19
Total Assets	$289.0M -32.9%	$430.3M -22.0%	$551.7M +2.3%	$539.3M +18.7%	$454.5M +24.3%	$365.6M
Operating Cash Flow	$-125.2M +26.7%	$-170.9M +17.8%	$-207.8M -26.9%	$-163.8M -6.3%	$-154.1M -77.5%	$-86.8M
Free Cash Flow	$-125.2M +26.8%	$-171.1M +17.9%	$-208.4M -25.3%	$-166.3M -3.8%	$-160.2M -82.9%	$-87.6M

Get alerted when ZNTL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Zentalis Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ZNTL

5AM Venture Management, LLC
$19.1M3,947,913 sh
BlackRock, Inc.
$18.2M3,753,525 sh
Squadron Capital Management LLC
$17.9M3,700,000 sh
TWO SIGMA INVESTMENTS, LP
$14.7M3,024,936 sh
VANGUARD CAPITAL MANAGEMENT LLC
$13.8M2,835,669 sh
ACADIAN ASSET MANAGEMENT LLC
$13.0M2,681,900 sh
CITADEL ADVISORS LLC
$11.1M2,298,403 sh
RENAISSANCE TECHNOLOGIES LLC
$7.8M1,609,078 sh
Opaleye Management Inc.
$6.9M1,412,656 sh
ORBIMED ADVISORS LLC
$6.7M1,390,576 sh

Fund	Value	Shares
5AM Venture Management, LLC	$19.1M	3,947,913
BlackRock, Inc.	$18.2M	3,753,525
Squadron Capital Management LLC	$17.9M	3,700,000
TWO SIGMA INVESTMENTS, LP	$14.7M	3,024,936
VANGUARD CAPITAL MANAGEMENT LLC	$13.8M	2,835,669
ACADIAN ASSET MANAGEMENT LLC	$13.0M	2,681,900
CITADEL ADVISORS LLC	$11.1M	2,298,403
RENAISSANCE TECHNOLOGIES LLC	$7.8M	1,609,078
Opaleye Management Inc.	$6.9M	1,412,656
ORBIMED ADVISORS LLC	$6.7M	1,390,576

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ZNTL on your watchlist

Track score changes the day Zentalis Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ZNTL a good stock to buy?

13F Pro's AI-powered analysis of Zentalis Pharmaceuticals, Inc. (ZNTL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ZNTL are available on the ZNTL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ZNTL is classified as a small company.

Which hedge funds own ZNTL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ZNTL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Zentalis Pharmaceuticals, Inc.'s investment landscape.